5/19/2023

Capecitabine Tablets

Products Affected - Description

- Capecitabine oral tablet, Accord, 150 mg, bottle, 60 count, NDC 16729-0072-12
- Capecitabine oral tablet, Accord, 500 mg, bottle, 120 count, NDC 16729-0073-29
- Capecitabine oral tablet, Areva, 500 mg, bottle, 120 count, NDC 59923-0722-12
- Capecitabine oral tablet, Armas Pharmaceuticals, 150 mg, bottle, 60 count, NDC 72485-0204-60
- Capecitabine oral tablet, Armas Pharmaceuticals, 500 mg, bottle, 120 count, NDC 72485-0205-12
- Capecitabine oral tablet, Dr. Reddy's, 150 mg, bottle, 60 count, NDC 55111-0496-60
- Capecitabine oral tablet, Dr. Reddy's, 500 mg, bottle, 120 count, NDC 55111-0497-04
- Capecitabine oral tablet, Eugia US, 150 mg, bottle, 60 count, NDC 59651-0204-60
- Capecitabine oral tablet, Eugia US, 500 mg, bottle, 120 count, NDC 59651-0205-08
- Capecitabine oral tablet, Hikma, 150 mg, bottle, 60 count, NDC 00054-0271-21
- Capecitabine oral tablet, Hikma, 500 mg, bottle, 120 count, NDC 00054-0272-23
- Capecitabine oral tablet, Teva, 150 mg, bottle, 60 count, NDC 00093-7473-06
- Capecitabine oral tablet, Teva, 500 mg, bottle, 120 count, NDC 00093-7474-89

Reason for the Shortage

- Accord has cabecitabine tablets on manufacturing back order.
- Areva did not provide a reason for the shortage.
- Armas did not provide a reason for the shortage.
- Dr. Reddy's has not provided availability updates at this time.
- Eugia has capecitabine tablets on shortage due to increased demand.
- Genentech has Xeloda available.
- Hikma did not provide a reason for the shortage.
- Novadoz has capecitabine tablets available.
- Teva did not provide a reason for the shortage.

Available Products

- Xeloda oral tablet, Genentech, 150 mg, bottle, 60 count, NDC 00004-1100-20
- Xeloda oral tablet, Genentech, 500 mg, bottle, 120 count, NDC 00004-1101-50
- Capecitabine oral tablet, Novadoz, 150 mg, bottle, 60 count, NDC 72205-0006-60
- Capecitabine oral tablet, Novadoz, 500 mg, bottle, 120 count, NDC 72205-0007-92

Estimated Resupply Dates

- Accord has capecitabine 150 mg tablets on intermittent back order and the company is releasing product as it becomes available. The 500 mg tablets are on back order and the company cannot estimate a release date.
- Areva has capecitabine 150 mg and 500 mg tablets on back order and the company cannot estimate a release date.
- Armas has capecitabine 150 mg and 500 mg tablets on back order and the company cannot estimate a release date.
- Dr. Reddy's has capecitabine 150 mg and 500 mg tablets available to current customers only.
- Eugia has capecitabine 150 mg and 500 mg tablets on allocation.
- Hikma has capecitabine 150 mg and 500 mg tablets on back order and the company cannot estimate a release date.
- Teva has capecitabine 150 mg and 500 mg tablets on back order and the company estimates a release date of mid-June 2023 for the 150 mg tablets and late-May 2023 for the 500 mg tablets.

Updated

Updated May 19, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 6, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.